Skip to main navigation

Our Science
Pipeline & Programs
About Us
Life at Arvinas
Patients
Investors + Media

>> Sub navigation

Careers
Contact

Investors + Media: Press Releases

Press Releases

Year

December 28, 2020

Arvinas, Inc. Announces Exercise of Underwriters’ Option to Purchase Additional Shares

December 15, 2020

Arvinas, Inc. Announces Pricing of $400 Million Public Offering of Common Stock

December 14, 2020

Arvinas, Inc. Announces Proposed Offering of Common Stock

December 14, 2020

Arvinas Releases Interim Clinical Data Further Demonstrating the Powerful Potential of PROTAC® Protein Degraders ARV-471 and ARV-110

December 11, 2020

Arvinas to Host Webcast Presentation of New Clinical Data from ARV-471 and ARV-110 PROTAC® Protein Degrader Development Programs

November 25, 2020

Arvinas to Participate in Upcoming Virtual Investor Conferences

November 5, 2020

Arvinas Reports Third Quarter 2020 Financial Results and Provides Corporate Update

October 14, 2020

Arvinas Announces Pipeline Programs Targeting Validated and Classically “Undruggable” Disease-Causing Proteins

October 6, 2020

Arvinas to Present at the 3rd Annual Targeted Protein Degradation Summit

September 4, 2020

Arvinas to Present at the Citi 15th Annual BioPharma Virtual Conference

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Tools

Email Alerts
RSS Feeds
Print Page
Email Page

Leading the way in targeted protein degradation therapeutics.

Join our team of experts

Follow Us https://www.linkedin.com/company/arvinas/ https://twitter.com/ArvinasInc

©2021. All Rights Reserved.

Contact Privacy Policy Terms & Conditions